Methods to identify and characterize developmental neurotoxicity for human health risk assessment. III: pharmacokinetic and pharmacodynamic considerations.
about
Introduction: reviews of environmental health, 2001.Lactational state modifies alcohol pharmacokinetics in women.A retrospective performance assessment of the developmental neurotoxicity study in support of OECD test guideline 426Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies.Epigallocatechin gallate (EGCG) inhibits adhesion and migration of neural progenitor cells in vitro.A 'best practices' approach to neuropathologic assessment in developmental neurotoxicity testing--for today.Adverse effects of lactational exposure to chlorpyrifos in suckling rats.Lactational exposure to abamectin induced mortality and adverse biochemical and histopathological effects in suckling pups.
P2860
Q24814048-092A4C88-F8A2-4CC8-8136-9CF5BE182257Q36492094-893A9D19-2C78-47AC-B255-D225426FD049Q37064795-90E6A074-F5E5-4CB3-AB17-673A63093B3DQ38003479-6632C8A9-BF03-405B-9095-A26A174786C9Q39820524-F81F8E96-0724-4F54-8888-6475213CCF50Q40325744-42007F1C-A6F7-483F-89E2-0E41D7E13E78Q43211477-6F464A38-10FF-4EBC-9797-D6A47F3D184EQ46304996-67FC7C8E-6BA7-4A40-999C-2F773D864F3E
P2860
Methods to identify and characterize developmental neurotoxicity for human health risk assessment. III: pharmacokinetic and pharmacodynamic considerations.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Methods to identify and charac ...... pharmacodynamic considerations
@nl
Methods to identify and charac ...... harmacodynamic considerations.
@ast
Methods to identify and charac ...... harmacodynamic considerations.
@en
type
label
Methods to identify and charac ...... pharmacodynamic considerations
@nl
Methods to identify and charac ...... harmacodynamic considerations.
@ast
Methods to identify and charac ...... harmacodynamic considerations.
@en
prefLabel
Methods to identify and charac ...... pharmacodynamic considerations
@nl
Methods to identify and charac ...... harmacodynamic considerations.
@ast
Methods to identify and charac ...... harmacodynamic considerations.
@en
P2093
P2860
P921
P356
P1476
Methods to identify and charac ...... harmacodynamic considerations.
@en
P2093
Byczkowski JZ
Fisher JE Jr
Mileson BE
P2860
P304
P356
10.1289/EHP.01109S1101
P407
P478
109 Suppl 1
P577
2001-03-01T00:00:00Z